TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05048836

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food Subsidy, 6 months
Description: Food subsidy for 6 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food Subsidy, 6 months
Description: Food subsidy for 6 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food Subsidy, 12 months
Description: Food subsidy for 12 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food Subsidy, 12 months
Description: Food subsidy for 12 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Support, 6 months
Description: lifestyle support intervention delivered by community health workers for 6 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Support, 6 months
Description: lifestyle support intervention delivered by community health workers for 6 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Support, 12 months
Description: lifestyle support intervention delivered by community health workers for 6 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Support, 12 months
Description: lifestyle support intervention delivered by community health workers for 6 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food Delivery, 6 months
Description: Twice monthly delivery of healthy food for 6 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food Delivery, 6 months
Description: Twice monthly delivery of healthy food for 6 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food Delivery, 12 months
Description: Twice monthly delivery of healthy food for 12 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food Delivery, 12 months
Description: Twice monthly delivery of healthy food for 12 months
Study: NCT05077475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C52R1H Tab. and C52R2 Tab.
Description: Single oral dose C52R1H(FDC, Valsartan/Amlodipine) 160/10 mg tablet and C52R2(Chlorthalidone) 25 mg tablet taken together

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C52R1H Tab. and C52R2 Tab.
Description: Single oral dose C52R1H(FDC, Valsartan/Amlodipine) 160/10 mg tablet and C52R2(Chlorthalidone) 25 mg tablet taken together

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AJU-C52L
Description: Single oral dose AJU-C52(Valsartan/Amlodipine/Chlorthalidone) 80/5/12.5 mg FDC 2 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AJU-C52L
Description: Single oral dose AJU-C52(Valsartan/Amlodipine/Chlorthalidone) 80/5/12.5 mg FDC 2 tablet
Study: NCT05538832

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BrainHQ Computerized Cognitive Training - Visual Perception Training Paradigm
Description: The Cognitive Training is a program consisting of the follow set of exercises developed by Posit Science Corporation (BrainHQ) which is to be evaluated for Visual Perception Training: Visual Sweeps; Mind's Eye; Hawk Eye; and Divided Attention. Participants use a standard web browser on a broadband connected computer and go to the study web site. Participants perform multiple trials over the course of a session, with auditory/visual feedback and rewards to indicate if the trial was performed correctly or incorrectly. After each assigned session, the difficulty of the next session is updated to ensure that each participant is appropriately challenged.
Study: NCT06764641

Intervention type: DIAGNOSTIC_TEST
Intervention: Breath test
Description: Participants must be fasted for a minimum of six hours prior to breath sample collection. Breath samples will be collected prior to the reference test for each participant (i.e. upper/lower gastrointestinal endoscopy, CT/MRI/ultrasound ± histological/cytology)
Study: NCT06764485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986365
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986365
Description: Specified dose on specified days
Study: NCT05538832

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BrainHQ Computerized Cognitive Training - Visual Cognitive Control Training Paradigm
Description: The Cognitive Training is a program consisting of the follow set of exercises developed by Posit Science Corporation (BrainHQ) which is to be evaluated for Visual Cognitive Control Training: Mind Bender; Divided Attention; Card Shark; and Freeze Frame. Participants use a standard web browser on a broadband connected computer and go to the study web site. Participants perform multiple trials over the course of a session, with auditory/visual feedback and rewards to indicate if the trial was performed correctly or incorrectly. After each assigned session, the difficulty of the next session is updated to ensure that each participant is appropriately challenged.
Study: NCT06102590

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized red blood cell transfusion strategy
Description: Prescription of RCBT is restricted to patients who present Hb ≤ 9.0 g/dL and O2ER ≥ 30%.
Study: NCT06764485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986365
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Predinsone/Prednisolone
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Predinsone/Prednisolone
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Predinsone/Prednisolone
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Predinsone/Prednisolone
Description: Specified dose on specified days
Study: NCT06764615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zasocitinib
Description: Zasocitinib capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zasocitinib
Description: Zasocitinib capsules.
Study: NCT06769373

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whirlpool Bath
Description: This group of participants will receive an exercise program consisting of 40 minutes hand-wrist range of motion exercises (passive, active assistive), stretching, strengthening exercises, whirlpool bath (32-38 °C) 20 minutes in total, transcutaneous electrical nerve stimulation (TENS) 20 minutes in total for 4 weeks. 5 sessions per week for 20 sessions in the Physical Therapy department.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contrast Bath
Description: This group of participants will recieve an exercise program consisting of 40 minutes hand-wrist range of motion exercises (passive, active assistive), stretching, strengthening exercises, contrast bath therapy which consist of 4 minutes hot water (38°C) followed by 1 minute cold water (10°C) periods for 20 minutes in total, transcutaneous electrical nerve stimulation (TENS) 20 minutes in total for 4 weeks. 5 sessions per week for 20 sessions in the Physical Therapy department.
Study: NCT05841420

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine monotherapy, 1000 mg/m2 weekly on days 1, 8, and 15 every 4 weeks or gemcitabine: 800 mg/m2 on day 1, 8 and 15 every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine monotherapy, 1000 mg/m2 weekly on days 1, 8, and 15 every 4 weeks or gemcitabine: 800 mg/m2 on day 1, 8 and 15 every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Nab-Paclitaxel: 100mg/m2 on day 1, 8 and 15 every 4 weeks
Study: NCT06769451

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Arrhythmia Radioablation (STAR) with Proton Therapy
Description: STAR with a single dose of 25Gy(RBE) Proton Therapy
Study: NCT06762366

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Additional Incentive
Description: During this behavioral intervention, participants will be given additional compensation for correct answers.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Response Delay
Description: During this behavioral intervention, participants will not be allowed to respond with their judgements until after a certain amount of time has passed.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Baseline Performance
Description: In this intervention, the participant completes the task as it is typically administer for a baseline performance measure. The participant can respond at will and does not receive incentive for correct responses.
Study: NCT06755294

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vestibular incision subperiostal tunnel technique
Description: The VISTA (Vestibular Incision Subperiosteal Tunnel Access) technique is a minimally invasive surgical approach for root coverage. A single vertical incision is made, often at the labial frenulum for optimal access, reaching the periosteum to elevate a subperiosteal tunnel. This tunnel is extended beyond the mucogingival junction and interproximally under each papilla to enable tension-free coronal repositioning of the gingiva.~An autologous connective tissue graft, harvested and de-epithelialized from the palate, is introduced into the tunnel. Before placement, teeth are etched (orthophosphoric or hydrofluoric acid depending on surface type). Sutures (6-0 polypropylene) stabilize the graft, with additional composite fixation on treated teeth. The vertical incision is closed using 5-0 sutures, ensuring proper stabilization and healing. This approach minimizes trauma, promotes healing, and achieves effective root coverage.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CAF
Description: The Coronally Advanced Flap (CAF) is an effective technique for root coverage in single or multiple gingival recession cases with adequate apical keratinized tissue thickness and height. Following the De Sanctis and Zucchelli protocol (2007), two horizontal incisions are made 3 mm apart, with placement 1 mm apical to the recession height. Vertical beveled incisions extend into the alveolar mucosa, and a flap is elevated in three stages: partial thickness at the papilla, full thickness to the buccal bone table, and apical partial thickness to release muscle fibers for mobility.~An autologous connective tissue graft (≥1 mm thick) is harvested from the palatal or retromolar area, de-epithelialized, and shaped to the recession size. The anatomical papillae are de-epithelialized, and the graft is sutured apically to the CEJ using 6-0 Polyglactin 910. Sling sutures (6-0 polypropylene) stabilize the flap 2 mm coronally to the CEJ, ensuring optimal positioning and healing.
Study: NCT06768905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iomab-B
Description: single 50 mCi dose of 131I-Apamistamab given prior to CAR-T cell infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iomab-B
Description: single 50 mCi dose of 131I-Apamistamab given prior to CAR-T cell infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAR-T cell
Description: CAR-T cell therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAR-T cell
Description: CAR-T cell therapy
Study: NCT05986318

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: N-Acetyl cysteine
Description: NAC capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: N-Acetyl cysteine
Description: NAC capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone Oral
Description: Dexamethasone tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone Oral
Description: Dexamethasone tablets

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: N-Acetyl cysteine Placebo
Description: Matching placebo for NAC capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: N-Acetyl cysteine Placebo
Description: Matching placebo for NAC capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone Placebo
Description: Matching placebo for dexamethasone tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone Placebo
Description: Matching placebo for dexamethasone tablets
Study: NCT06102590

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: European guidelines red blood cell transfusion strategy
Description: RBCT according to ESICM guidelines
Study: NCT05512065

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound scan of the right and left uterine arteries and umbilical artery.
Study: NCT05986318

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: All participants will receive radical pulmonary radiation therapy. Conventional techniques or stereotactic ablative radiotherapy will be used.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: All participants will receive radical pulmonary radiation therapy. Conventional techniques or stereotactic ablative radiotherapy will be used.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: All participants will receive radical pulmonary radiation therapy. Conventional techniques or stereotactic ablative radiotherapy will be used.

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Radiation Therapy
Description: All participants will receive radical pulmonary radiation therapy. Conventional techniques or stereotactic ablative radiotherapy will be used.
Study: NCT06759389

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resuscitation (Ventor)
Description: Resuscitation with the Ventor device
Study: NCT06762444

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech-language pathologist (SLP) protocol
Description: The SLP intervention protocol consists of six components, all of which will be implemented by the treating speech-language pathologist
Study: NCT06768593

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RIFP Block
Description: After aseptic conditions are ensured, with high-frequency linear US probe (11-12 MHz, Vivid Q) and a 22-G 80-mm needle (Pajunk Sonoplex Nanoline Stim Cannula, Germany) bilateral block will be applied to Group R. As the patient is in supine position, the USG probe is placed in transverse plane on the sternum and will be directed downwards and laterally and rotated to determine the xiphoid and just below the rectus abdominis muscles. Costal cartilage and rectus abdominis muscle sonographically will be shown. This region corresponds to the 3-4 cm lateral and 3-4 cm caudal region of the xiphoid. Using the in-plane technique, the block needle will be advanced in the caudal-cephalic direction, and 5 ml saline will be injected into the area between the rectus muscle and costal cartilage to verify the block location. 30 ml of 0.25% bupivacaine (Buvacaine, Polifarma ®) will be injected to each side, which corresponds to 60 ml total local anesthetic-saline mixture in Group R.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative pain management
Description: Ibuprofen 400 mg (Ibuprofen, Polifarma ®) and tramadol 100 mg (Contramal, Abdi İbrahim ®) IV single bolus dose will be given 20 minutes before the end of the surgical procedure for postoperative analgesia.~NRS scores at rest and while moving will be evaluated and recorded and if the NRS score is ≥ 4, meperidine 0,5 mg/kg (Aldolan®) IV will be administered as a rescue analgesic.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postoperative pain management
Description: Ibuprofen 400 mg (Ibuprofen, Polifarma ®) and tramadol 100 mg (Contramal, Abdi İbrahim ®) IV single bolus dose will be given 20 minutes before the end of the surgical procedure for postoperative analgesia.~NRS scores at rest and while moving will be evaluated and recorded and if the NRS score is ≥ 4, meperidine 0,5 mg/kg (Aldolan®) IV will be administered as a rescue analgesic.
Study: NCT06693011

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contour Neurovascular System Treatment Attempt
Description: The subject is brought into the procedure room, an angiogram on the day of the procedure indicates that the subject is anatomically eligible for the trial and any part of the investigational device comes in contact with the patient
Study: NCT06773975

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplementation
Description: The oral nutritional supplement is a locally made plant based formulation targeted to improve the nutritional status of the elderly
Study: NCT06772493

Intervention type: DEVICE
Intervention: ViewFlex X ICE System
Description: Subjects to undergo cardiac ablation procedure utilizing the ViewFlex X ICE System

Intervention type: DEVICE
Intervention: ViewFlex X ICE System
Description: Subjects to undergo cardiac ablation procedure utilizing the ViewFlex X ICE System
Study: NCT06776432

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sivopixant
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SASS-001
Description: Administered as specified in the treatment arm
Study: NCT06776341

Intervention type: OTHER
Intervention: GEMIN5-Related Neurodevelopmental Disorder
Description: This is an observational study. The investigators will collect data from participants' medical records regarding neurodevelopmental outcomes (eg. cognitive, speech and language, motor skills, developmental skills, vision, hearing), Time to event (Acquistion and loss of developmental milestones), and, if available, data regarding MRIs (presence of cerebellar atrophy), survival, visiion, hearing, and biomarkers of disease.
Study: NCT06776549

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Temperature control
Description: Procedure: Temperature control at 33-34 °C In the hypothermia group, patients receiving ECPR will be immediately cooled to 33ºC-34ºC with ECMO using a heat exchanger. After reaching this targeted temperature, the maintenance phase will start, and the target temperature will be kept at 33ºC-34°C. The maintenance phase will end 24 h after reaching this targeted temperature. Subsequently, rewarming to 36ºC-37ºC will be conducted in 24 h. After the rewarming, the temperature will be kept in the range of 36ºC-37.5ºC for 24 h after rewarming or until the end of ECMO, and should not exceed 37.5ºC. Other interventions, such as sedation, administration of neuromuscular blocking agents, antipyretics, and catecholamines, as well as mechanical circulatory support, are optional and performed at the patient's discretion.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Temperature control
Description: Procedure: Temperature control at 36 °C In the normothermia group receiving ECPR, the temperature of 36ºC will be immediately reached with ECMO using a heat exchanger. After reaching this targeted temperature, the maintenance phase will start, and the target temperature will be maintained at 36ºC. The maintenance phase will end 24 h after reaching this targeted temperature. Then, rewarming to 36ºC-37ºC will be conducted in 24 h. After the rewarming, the temperature will be kept in the range of 36ºC-37.5ºC for 24 h after rewarming or until the end of ECMO, and should not exceed 37.5ºC. Other interventions, such as sedation, administration of neuromuscular blocking agents, antipyretics, and catecholamines, as well as mechanical circulatory support, are optional and performed at the patient's discretion.
Study: NCT05504278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI351
Description: recommended dose, po
Study: NCT05820152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NFS-02 Injection
Description: The starting dose is 1.5×108 vg, 0.05 mL eye/dose. If drug-related dose-limiting toxicity (DLT) events are observed in \< 2 of the 6 evaluable subjects within 6 weeks after the dosing of NFS-02 at the starting dose, the dose can be escalated to 5.0×108 vg, 0.05 mL eye/dose after the approval by SRC. If drug-related dose-limiting toxicity (DLT) events are observed in \< 2 of the 6 evaluable subjects within 6 weeks after the dosing of NFS-02 at the 5.0×108 vg, 0.05 mL eye/dose, the dose can be escalated to 1.5×109 vg, 0.05 mL eye/dose after the approval by SRC. If drug-related dose-limiting toxicity (DLT) events are observed in ≥ 2 of the 6 evaluable subjects within 6 weeks after the dosing of NFS-02 at the starting dose, the dose can be de-escalated to 5.0×107 vg, 0.05 mL eye/dose after the approval by SRC.
Study: NCT04122183

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iManage (my hearing loss)
Description: An internet-based decision coaching guide to help an individual decide if they wish to visit an audiologist.
Study: NCT05422365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG), 10% solution for infusion
Description: The study drug is administrated at a dose 0.8-1.0 g / kg once a day for 2 consecutive days, the course dose is 1.6-2.0 g / kg.
Study: NCT06145633

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample colleciton

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT, PET/CT, SPECT/CT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Undergo FDG PET/CT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gallium Ga 68 Gozetotide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutetium Lu 177 Vipivotide Tetraxetan
Description: Given 177Lu-PSMA-617

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo 68Ga-PSMA-11 PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Photon Emission Computed Tomography
Description: Undergo SPECT/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given IV